News

bluebird bio corporate development and strategy oncology franchise leader and senior vice president Joanne Smith-Farrell said: "Entering into this co-development and co-promotion partnership with Celgene is a significant

Takeda announced that its consideration of such an offer is at a preliminary and exploratory stage and no approach has been made to the board of Shire. Shire

Daiichi Sankyo R&D Division Oncology Function head, executive officer Koichi Akahane said: "There are no HER2-targeting treatment options currently available for patients with HER2-positive gastric cancer whose tumors

This decision followed a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients from the ongoing

Pedmark, a formulation of sodium thiosulfate (STS), is a water-soluble thiol compound that serves as a chemical reducing agent. Delayed administration (between four to eight hours) of high dose

In 2015, the consumer healthcare JV was established, as part of a three-part inter-conditional transaction between GSK and Novartis. The JV is a combination of Novartis' over-the-counter (OTC)

The round was oversubscribed. Adagene CEO Peter Luo said: "Adagene is built on a proprietary discovery engine that we have leveraged to discover highly differentiated portfolio of agonist

Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition. It is based

Vobarilizumab is the firm’s anti-IL-6R Nanobody, which did not achieve the primary endpoint of dose response based on the modified BILAG-based combined lupus assessment (mBICLA) at week 24.